Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:03 UTC |
Leahy EmerDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 5,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001875180-26-000002 · wk-form4_1784577796.xml · derivative · entry 1 Leahy Emer · CIK 0001875180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:03 UTC |
Donovan DanielDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 5,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001934188-26-000002 · wk-form4_1784577834.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:02 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 11,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001895944-26-000008 · wk-form4_1784577777.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:01 UTC |
BENDER LEWIS HDirector · President and CEO
|
GrantStock Option (right to buy Common Stock) · Derivative | 78,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001238705-26-000007 · wk-form4_1784577657.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:04 UTC |
DUBIN THOMAS I HDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 5,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001231945-26-000002 · wk-form4_1784577849.xml · derivative · entry 1 DUBIN THOMAS I H · CIK 0001231945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:03 UTC |
GOLDBERG MARK ADirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 5,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001278042-26-000002 · wk-form4_1784577818.xml · derivative · entry 1 GOLDBERG MARK A · CIK 0001278042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:02 UTC |
Talamo JosephChief Financial Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 34,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001524547-26-000009 · wk-form4_1784577756.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:09 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantCommon Stock, $0.0001 Par Value | 3,688 | $3.49 | $12,852.68 |
DisclosureSEC source: 0001895944-26-000006 · wk-form4_1782936560.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,102 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026. F3 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:08 UTC |
Talamo JosephChief Financial Officer
|
GrantCommon Stock, $0.0001 Par Value | 1,093 | $3.49 | $3,809.11 |
DisclosureSEC source: 0001524547-26-000007 · wk-form4_1782936500.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026. F3 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 21:29 UTC |
BENDER LEWIS HDirector · President and CEO
|
GrantCommon Stock, $0.0001 Par Value | 37,749 | $6.11 | $230,646.39 |
DisclosureSEC source: 0001238705-26-000005 · wk-form4_1774901174.xml · nonDerivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,549 F1 · shares: Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request. F2 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:03 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantCommon Stock, $0.0001 Par Value | 8,918 | $0.26 | $2,336.52 |
DisclosureSEC source: 0001895944-26-000003 · wk-form4_1767647011.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,354 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:01 UTC |
Talamo JosephChief Financial Officer
|
GrantCommon Stock, $0.0001 Par Value | 14,482 | $0.26 | $3,794.28 |
DisclosureSEC source: 0001524547-26-000003 · wk-form4_1767646901.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,661 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:03 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantCommon Stock, $0.0001 Par Value | 69,745 | $0.26 | $18,203.45 |
DisclosureSEC source: 0001567264-25-000066 · wk-form4_1751486573.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,436 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:02 UTC |
Talamo JosephChief Financial Officer
|
GrantCommon Stock, $0.0001 Par Value | 14,179 | $0.26 | $3,700.72 |
DisclosureSEC source: 0001567264-25-000065 · wk-form4_1751486535.xml · nonDerivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,179 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:09 UTC |
Leahy EmerDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000030 · wk-form4_1746562121.xml · derivative · entry 1 Leahy Emer · CIK 0001875180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:11 UTC |
Donovan DanielDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000032 · wk-form4_1746562262.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:21 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000035 · wk-form4_1746562857.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:07 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000029 · wk-form4_1746561910.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:07 UTC |
BENDER LEWIS HDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy Common Stock) · Derivative | 700,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000028 · wk-form4_1746562022.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:11 UTC |
DUBIN THOMAS I HDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000033 · wk-form4_1746562305.xml · derivative · entry 1 DUBIN THOMAS I H · CIK 0001231945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:10 UTC |
GOLDBERG MARK ADirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000031 · wk-form4_1746562194.xml · derivative · entry 1 GOLDBERG MARK A · CIK 0001278042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:03 UTC |
Talamo JosephChief Financial Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 300,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000027 · wk-form4_1746561816.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:22 UTC |
Wesolowski John MPrincipal Accounting Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 70,028 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001895944-24-000014 · wk-form4_1729714943.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,028 Underlying: Common Stock · 70,028 shares Expires 2034-10-21 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:21 UTC |
Talamo JosephChief Financial Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 427,379 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001524547-24-000002 · wk-form4_1729714866.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,379 Underlying: Common Stock · 427,379 shares Expires 2034-10-21 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 11:26 UTC |
Wesolowski John MPrincipal Accounting Officer
|
Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001895944-24-000011 · wk-form4_1717759566.xml · derivative · entry 2 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2027-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of March 27, 2021. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 11:26 UTC |
Wesolowski John MPrincipal Accounting Officer
|
Exercise / conversionCommon Stock, $0.0001 Par Value | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001895944-24-000011 · wk-form4_1717759566.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to an inadvertent error, the Form 3 filed by the Reporting Person on June 29, 2023 incorrectly reported the amount of securities beneficially owned. This inadvertent error caused the amount of securities beneficially owned to be understated by 691 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following the reported transaction. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:35 UTC |
DUBIN THOMAS I HDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001567264-24-000019 · wk-form4_1715805281.xml · derivative · entry 1 DUBIN THOMAS I H · CIK 0001231945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: This option will vest, subject to Mr. Dubin's continued service, in four equal annual installments beginning on May 14, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:05 UTC |
Leahy EmerDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020834 · ownership.xml · derivative · entry 1 Leahy Emer · CIK 0001875180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:02 UTC |
Donovan DanielDirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020831 · ownership.xml · derivative · entry 1 Donovan Daniel · CIK 0001934188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:06 UTC |
Wesolowski John MSee Remarks
|
GrantStock Option (right to buy Common Stock) · Derivative | 25,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020835 · ownership.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2025. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:01 UTC |
BENDER LEWIS HDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy Common Stock) · Derivative | 33,574 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020830 · ownership.xml · derivative · entry 2 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,574 Underlying: Common Stock · 33,574 shares Expires 2034-03-06 F2 · derivative.exercise_date: This option vested 100% on March 6, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:01 UTC |
BENDER LEWIS HDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy Common Stock) · Derivative | 464,805 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020830 · ownership.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,805 Underlying: Common Stock · 464,805 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:03 UTC |
GOLDBERG MARK ADirector
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020832 · ownership.xml · derivative · entry 1 GOLDBERG MARK A · CIK 0001278042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 13:17 UTC |
Talamo JosephChief Financial Officer
|
GrantStock Option (right to buy Common Stock) · Derivative | 80,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001213900-23-094886 · ownership.xml · derivative · entry 1 Talamo Joseph · CIK 0001524547 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-12-11 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four equal, annual installments, beginning on December 11, 2024. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:11 UTC |
Wesolowski John MInterim CFO
|
GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001213900-23-058840 · ownership.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-07-19 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., according to the following schedule: 25% will vest on July 19, 2023, and the remaining 75% will vest in three, equal, annual installments, beginning on July 19, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.